Background: Infliximab is the fastest acting biological agent in psoriasis treatment due to the possibility of intravenous administration and a well-conducted induction phase of treatment (week ... responsible for the…
Infliximab is the fastest acting biologic agent due to intravenous administration and a well-conducted induction phase of treatment. The disadvantages include the risk of infusion reactions and the production…
TNFα was started. During a period of 14 weeks, he received 4 cyclеs of infliximab (5 mg/kg) in combination with azathioprine (100 mg). Despite the combination therapy, he failed ... respond and his perianal disease…
study: To evaluate effect of infliximab therapy in Iraqi patients with ulcerative colitis and Crohn`s diseases. Patients & Methods: A clinical prospective follow up study conducted in Gastroenterology and Hepatology…
corticosteroid or interferon. The aim of this study is to investigate the efficacy of infliximab treatment in patients with refractory uveitis associated with Behçet disease.Methods: Nine patients with Behçet disease…
Infliximab, a monoclonal antibody targeting tumor necrosis factor alpha (TNF-alpha), has revolutionized the management of chronic inflammatory diseases such as rheumatoid arthritis (RA) and Crohn's disease (CD). This…
woman who had been suffering from rheumatoid arthritis for five years started treatment with infliximab. The screening of a chest X-ray before initiating infliximab treatment showed no abnormal shadows ... After a month…
Infliximab is a chimeric, monclonal antibody against tumour necrosis factor α. Extending previous findings in other chronic inflammatory diseases, recent double-blind, placebocontrolled, randomized trials have provided…
therapy, some patients still experience pruritus. In this study, we evaluated the effect of infliximab on cholestatic pruritus induced in mice by bile duct ligation. Methods: Twenty-four balb ... treatment groups. After…
proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is a chimeric anti-TNF-α monoclonal antibody with high affinity for soluble and cell-surface transmembrane ... long-term…
ntroduction: To evaluate the efficacy of tumor necrosis factor inhibitor infliximab in patients with rheumatoid arthritis (RA) who were disease resistant to recombinant humaninterleukin-1 receptor antagonist (IL-1Ra)…
Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), has revolutionized the treatment landscape of chronic inflammatory diseases. This review comprehensively explores the mechanisms…
obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly ... Ulcerative Colitis…
treatment with colchicine and lack of clinical response to Anakinra, successfully treated with Infliximab. Our case suggests that Infliximab, an anti-TNF antibody, may represent a safe and effective therapy
Recently LABD has been reported in association with ulcerative colitis in which treatment with infliximab resolved both diseases. We describe a patient with ulcerative colitis who developed LABD disease after…
Background: Some patients with inflammatory bowel disease (IBD) do not respond to infliximab (IFX) therapy. Gene expression studies revealed genes that may help to predict non-responding IBD patients ... candidate genes…
allergic reaction to Adalimumab drug in an Ankylosing Spondylitis (AS) patient and switching to Infliximab. Case report: A 43-year-old middleeastern man with a history
Background: Infliximab (IFX) is used for the treatment of Crohn's disease (CD). However, there is still controversy on the efficacy and safety of IFX in CD patients. This study
Infliximab, a murine monoclonal antibody directed against TNF-α, has been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn’s disease that is unresponsive
rays or computed tomography (CT) abnormalities associated with IBD in patients treated with infliximab (IFX). Methods: We prospectively obtained, through interviews, information regarding respiratory symptoms, medical…
Objective: Few studies have correlated the infliximab (IFX) trough concentration, clinical remission (CM) and mucosal healing (MH). The purpose of the study was to determine if higher IFX trough levels
Biologic drugs, as Infliximab (IFX), are widely used in inflammatory bowel disease (IBD). IFX is a chimeric monoclonal immunoglobulin directed against TNF-α and acting in IBD through several mechanisms
Background and Aims: Infliximab (IFX) is one of the most potent and effective treatments for steroid- or immunomodulator-refractory ulcerative colitis (UC). We evaluated the early efficacy of IFX, based
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.